SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Unilife Corp – ‘10-Q’ for 12/31/13 – ‘R16’

On:  Monday, 2/10/14, at 4:59pm ET   ·   For:  12/31/13   ·   Accession #:  1193125-14-43402   ·   File #:  1-34540

Previous ‘10-Q’:  ‘10-Q’ on 11/12/13 for 9/30/13   ·   Next:  ‘10-Q’ on 5/12/14 for 3/31/14   ·   Latest:  ‘10-Q’ on 2/9/17 for 12/31/16

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/10/14  Unilife Corp                      10-Q       12/31/13   52:2.8M                                   Donnelley … Solutions/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    239K 
 2: EX-15       Letter re: Unaudited Interim Financial Information  HTML     17K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     22K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     18K 
 6: EX-32.2     Certification -- §906 - SOA'02                      HTML     18K 
34: R1          Document and Entity Information                     HTML     39K 
25: R2          Consolidated Balance Sheets                         HTML    111K 
32: R3          Consolidated Balance Sheets (Parenthetical)         HTML     42K 
36: R4          Consolidated Statements of Operations and           HTML     67K 
                Comprehensive Loss                                               
48: R5          Consolidated Statement of Stockholders' Equity      HTML     54K 
26: R6          Consolidated Statements of Cash Flows               HTML     91K 
31: R7          Description of Business and Unaudited Financial     HTML     22K 
                Statements                                                       
23: R8          Liquidity                                           HTML     24K 
17: R9          Summary of Significant Accounting Policies          HTML     30K 
49: R10         Equity Transactions and Share-Based Compensation    HTML     58K 
38: R11         Property, Plant and Equipment and                   HTML     29K 
                Construction-in-Progress                                         
37: R12         Goodwill                                            HTML     22K 
42: R13         Long-Term Debt                                      HTML     38K 
43: R14         Net Loss Per Share                                  HTML     35K 
41: R15         Contingencies                                       HTML     30K 
44: R16         Business Alliances                                  HTML     22K 
33: R17         Summary of Significant Accounting Policies          HTML     51K 
                (Policies)                                                       
35: R18         Equity Transactions and Share-Based Compensation    HTML     53K 
                (Tables)                                                         
40: R19         Property, Plant and Equipment and                   HTML     28K 
                Construction-in-Progress (Tables)                                
52: R20         Goodwill (Tables)                                   HTML     22K 
46: R21         Long-Term Debt (Tables)                             HTML     31K 
28: R22         Net Loss Per Share (Tables)                         HTML     30K 
39: R23         Liquidity - Additional Information (Detail)         HTML     28K 
30: R24         Equity Transactions and Share-Based Compensation -  HTML     49K 
                Additional Information (Detail)                                  
15: R25         Equity Transactions and Share-Based Compensation -  HTML     50K 
                Schedule of Stock Options Activity by Employees                  
                and Directors (Detail)                                           
47: R26         Equity Transactions and Share-Based Compensation -  HTML     55K 
                Schedule of Stock Options Activity by Other than                 
                Employees and Directors (Detail)                                 
50: R27         Equity Transactions and Share-Based Compensation -  HTML     31K 
                Fair Value of Options Granted (Detail)                           
20: R28         Equity Transactions and Share-Based Compensation -  HTML     40K 
                Summary of Activity Related to Restricted Stock                  
                Awards (Detail)                                                  
19: R29         Property, Plant and Equipment and                   HTML     45K 
                Construction-in-Progress - Components of Property,               
                Plant and Equipment and Construction-in-Progress                 
                (Detail)                                                         
21: R30         Goodwill - Changes in Carrying Amount of Goodwill   HTML     22K 
                (Detail)                                                         
22: R31         Long-Term Debt - Components of Long-Term Debt       HTML     32K 
                (Detail)                                                         
24: R32         Long-Term Debt - Components of Long-Term Debt       HTML     30K 
                (Parenthetical) (Detail)                                         
14: R33         Long-Term Debt - Additional Information (Detail)    HTML     75K 
45: R34         Net Loss Per Share - Net Loss Per Share (Detail)    HTML     37K 
27: R35         Net Loss per Share - Additional Information         HTML     27K 
                (Detail)                                                         
29: R36         Business Alliances - Additional Information         HTML     30K 
                (Detail)                                                         
51: XML         IDEA XML File -- Filing Summary                      XML     73K 
13: EXCEL       IDEA Workbook of Financial Reports                  XLSX     87K 
18: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    306K 
 7: EX-101.INS  XBRL Instance -- unis-20131231                       XML    549K 
 9: EX-101.CAL  XBRL Calculations -- unis-20131231_cal               XML    131K 
10: EX-101.DEF  XBRL Definitions -- unis-20131231_def                XML    285K 
11: EX-101.LAB  XBRL Labels -- unis-20131231_lab                     XML    713K 
12: EX-101.PRE  XBRL Presentations -- unis-20131231_pre              XML    501K 
 8: EX-101.SCH  XBRL Schema -- unis-20131231                         XSD     98K 
16: ZIP         XBRL Zipped Folder -- 0001193125-14-043402-xbrl      Zip     82K

‘R16’   —   Business Alliances

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v2.4.0.8
Business Alliances
 6 Months Ended
Text Block [Abstract]  
Business Alliances

10. Business Alliances

Sanofi

The Company signed an exclusivity agreement and an industrialization agreement with Sanofi, a multinational pharmaceutical company, between June 2008 and July 2009. Under the terms of these agreements, Sanofi had agreed to pay the Company an aggregate of approximately $36.4 million in exclusivity fees and industrialization milestone payments for the exclusive right to negotiate the purchase of the Unifill ready-to-fill (prefilled) syringe (Unifill syringe or product) which was developed pursuant to the agreements. Sanofi had paid the Company a €10.0 million ($13.0 million) up front non-refundable one-time fee which the Company was recognizing as revenue over the expected term of the agreement.

On September 3, 2013, the Company and Sanofi entered into a supply agreement and terminated both the exclusivity agreement and the industrialization agreement. As a result, the Company has recognized the remaining unamortized revenue of $2.3 million during the six months ended December 31, 2013. Under the terms of the supply agreement, the Company has granted Sanofi the exclusive use of the Unifill Finesse with anti-thrombotic drugs during the contract period. Following a four year ramp-up period after market entry, exclusivity will be maintained, subject to Sanofi purchasing a minimum of 150 million units of the Unifill Finesse or other Unifill syringes per year. The Company can supply its Unifill syringes, including the Unifill Finesse, to additional customers in all other therapeutic classes outside of anti-thrombotics. In addition to future revenue from the sale of Unifill Finesse syringes, the Company may receive up to $15 million from Sanofi in milestone-based payments with $5.0 million of these payments received in October 2013. This supply contract replaces and supersedes all other agreements previously signed between both parties regarding the Unifill syringe platform.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:2/10/148-K
For Period end:12/31/13SD
9/3/138-K
 List all Filings 
↑Top
Filing Submission 0001193125-14-043402   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 14, 10:11:06.1pm ET